Last Update Time:
20-Mar-2025 16:00:00
ISIN:
INE159A01016
Sector:
Healthcare
Symbol:
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
₹2,860.00
₹21.70
(0.76%)
▲
Prev. Close
₹2,838.30
Open
₹2,850.00
Close
₹2,860.50
Range
₹2,717.00 - ₹3,003.00
High
₹2,921.20
Low
₹2,832.05
Ind. Close
₹0.00
VWAP
₹2,873.54
The current stock price of GlaxoSmithKline Pharmaceuticals Limited is ₹2,860.00, with a target price range between ₹2,717.00 and ₹3,003.00. The stock has experienced a price change of ₹21.70 (0.76%), reflecting recent market volatility.
Today's opening price was ₹2,850.00, while the previous close stood at ₹2,838.30.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
GlaxoSmithKline Pharmaceuticals Limited Price Chart
GlaxoSmithKline Pharmaceuticals Limited Pre Open Market Overview: 20-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 2850
- Previous Close Price: 2838.3
- Change: 11.70%
- Total Traded Volume: 727
- Total Buy Quantity: 1,000
- Total Sell Quantity: 4,962
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 2,809.95 | 5.00 | 0.00 |
| 2,825.00 | 3.00 | 0.00 |
| 2,838.30 | 72.00 | 0.00 |
| 2,839.00 | 4.00 | 0.00 |
| 2,840.00 | 105.00 | 0.00 |
| 2,850.00 | 0.00 | 199.00 |
| 2,852.45 | 0.00 | 3.00 |
| 2,855.00 | 0.00 | 6.00 |
| 2,856.60 | 0.00 | 1.00 |
| 2,858.30 | 0.00 | 2.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 2,860.50 | 67 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 1000
Total Sell Quantity: 4962
Shareholding Patterns of GlaxoSmithKline Pharmaceuticals Limited
Key Trade Statistics of GlaxoSmithKline Pharmaceuticals Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 1.44 |
| Traded Value (₹ Cr.) | 41.32 |
| Total Market Cap (₹ Cr.) | 48,450.13 |
| Free Float Market Cap (₹ Cr.) | 11,807.34 |
| Impact cost | 0.05 |
| Quantity Traded | 143,779.00 |
| Deliverable Quantity | 51,065.00 |
| % of Quantity to Traded | 35.52 |
| Security VaR | 15.68 |
| Index VaR | N/A |
| VaR Margin | 15.68 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 19.18 |
| Face Value | 10 |
Key Price Statistics of GlaxoSmithKline Pharmaceuticals Limited
The 52-week high for GlaxoSmithKline Pharmaceuticals Limited was ₹3,088.00, recorded on 21-Aug-2024. On the other hand, the 52-week low stands at ₹1,842.05, with the lowest value recorded on 15-Apr-2024.
The upper band for trading is ₹3,405.95, and the lower band is ₹2,270.65. The price band is 20%.
The stock's daily volatility stands at 2.43, while the annualized volatility is 46.43. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (21-Aug-2024) | 3,088.00 |
| 52 Week Low (15-Apr-2024) | 1,842.05 |
| Upper Band | 3,405.95 |
| Lower Band | 2,270.65 |
| Price Band (%) | 20 |
| Daily Volatility | 2.43 |
| Annualised Volatility | 46.43 |
| Tick Size | 0.05 |
Key Securities Statistics of GlaxoSmithKline Pharmaceuticals Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 15-Dec-2000 |
| Adjusted P/E | 56.3 |
| Symbol P/E | 55.96 |
| Index | NIFTY 500 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of GlaxoSmithKline Pharmaceuticals Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of GlaxoSmithKline Pharmaceuticals Limited
| Subject | Date |
|---|---|
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 10-Mar-2025 |
| Appointment | 03-Mar-2025 |
| Resignation | 03-Mar-2025 |
| Action(s) initiated or orders passed | 28-Feb-2025 |
| Action(s) initiated or orders passed | 28-Feb-2025 |
| Rumour Verification - Regulation 30(11) | 25-Feb-2025 |
| Rumour Verification - Regulation 30(11) | 18-Feb-2025 |
| Copy of Newspaper Publication | 17-Feb-2025 |
Corporate Actions of GlaxoSmithKline Pharmaceuticals Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 10 | Interim Dividend - Rs 12 Per Share | 07-Nov-2024 |
| 10 | Dividend - Rs 32 Per Share | 31-May-2024 |
| 10 | Dividend - Rs 32 Per Share | 30-Jun-2023 |
| 10 | Dividend - Rs 30 Per Share/Special Dividend- Rs 60 Per Share | 07-Jul-2022 |
| 10 | Annual General Meeting/Dividend - Rs 30 Per Share | 19-Jul-2021 |
| 10 | Dividend - Rs 20 And Special Dividend - Rs 20 Per Share | 17-Jul-2020 |
| 10 | Annual General Meeting/Dividend Rs 20 Per Share | 11-Jul-2019 |
| 10 | Bonus 1:1 | 11-Sep-2018 |
| 10 | Dividend- Rs 35 Per Share | 13-Jul-2018 |
| 10 | Dividend - Rs 30/- Per Share | 14-Jul-2017 |
| 10 | Dividend Rs 50/- Per Share | 15-Jul-2016 |
| 10 | Annual General Meeting/Dividend - Rs 62..50/- Per Share | 23-Jul-2015 |
| 10 | Final Dividend Rs.50/- Per Share | 03-Apr-2014 |
| 10 | Dividend Rs. 50 Per Share | 04-Apr-2013 |
| 10 | Dividend Rs.45/- Per Share | 29-Mar-2012 |
| 10 | Dividend-Rs.40/- Per Share | 14-Mar-2011 |
| 10 | Dividend-Rs.30/- Pr Share | 10-Mar-2010 |
| 10 | Div Fin-Rs.22 + Spl-Rs.18 | 18-Mar-2009 |
| 10 | Div Fin-Rs18+Spl-18 Pr Sh | 02-Apr-2008 |
| 10 | Div Fin-170% + Spl-140% Purpose Revised | 14-Mar-2007 |
Board Meetings of GlaxoSmithKline Pharmaceuticals Limited
Financial Results of GlaxoSmithKline Pharmaceuticals Limited
Company Directory of GlaxoSmithKline Pharmaceuticals Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.gsk-india.com | Head Office/ Corporate Office | Dr Annie Besant Road Worli | MUMBAI |
| www.gsk-india.com | Registered Office | Dr Annie Besant Road Worli | MUMBAI |
| www.gsk-india.com | Transfer Agent | Karvy Computershare Private Limited, Plot No. 17 to 24, Vithal Rao Nagar, Madhapur, | HYDERABAD |
Insider Trading of GlaxoSmithKline Pharmaceuticals Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Castleton Investment Ltd | 8698848550 | Sell |
| 7(2) | GlaxoSmithKline Pte Ltd | 8698848550 | Buy |
Annual Reports of GlaxoSmithKline Pharmaceuticals Limited
Investor Complaints of GlaxoSmithKline Pharmaceuticals Limited
Event Calendar of GlaxoSmithKline Pharmaceuticals Limited
| Purpose | Details |
|---|---|
| Results/Others | To Consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2010. |
| Results/Dividend | Inter-alia, to consider amongst other things, approval of audited financial results for the year ended December 31, 2010 and to recommend dividend, if any, on the equity shares of the Company. |
| Results/Others | Inter-alia, to consider amongst other things, approval of unaudited financial results for the quarter April-June 2011 (Q2) and half-year January-June 2011. |
| Results/Others | To consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2011. |
| Results/Dividend | Inter-alia, to consider amongst other things, approval of audited financial results for the year ended December 31, 2011 and to recommend dividend, if any, on the equity shares of the Company. |
| Results/Others | To consider amongst other things, approval of unaudited financial results for the quarter ended March 31, 2012. |
| Results/Others | Inter-alia, to consider amongst other things, approval of unaudited financial results for the quarter April-June 2012 (Q2) and half-year January-June 2012. |
| Results/Dividend | Inter-alia, to consider amongst other things, approval of audited financial results for the year ended December 31, 2012 and to recommend dividend, if any, on the equity shares of the Company. |
| Others | To consider and approve re-constitution and adopt the terms of references of the following Sub-Committees of the Board : (1) Audit Committee; (2) Investor Grievance Committee; (3) Remuneration Committee. |
| Results/Others | To consider amongst other things, approval of unaudited financial results for the quarter ended March 31, 2013. |
| Results/Others | Inter-alia, to consider amongst other things, approval of unaudited financial results for the quarter April-June 2013 (Q2) and half-year January-June 2013. |
| Results/Others | To consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2013. |
| Results/Dividend | inter-alia, to consider amongst other things, approval of audited financial results for the year ended December 31, 2013 and to recommend dividend, if any, on the equity shares of the Company. |
| Results | to consider amongst other things, approval of unaudited financial results for the quarter ended March 31, 2014. |
| Results/Others | To consider amongst other things, approval of unaudited financial results for the quarter ended March 31,2014. |
| Results | to consider unaudited financial results for the quarter April-June 2014 and Half year ended June 30, 2014. The trading window for dealing in securities will remain closed until August 14, 2014 for all designated employees, directors etc pursuant to applicable SEBI regulations. |
| Results/Others | To consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2014. |
| Results | To consider amongst other things, approval of unaudited financial results for the 4th quarter ended December 31, 2014. |
| Results/Dividend | Inter-alia, to consider amongst other things, approval of audited financial results for the fifteen months period ended March 31, 2015 and to recommend dividend, if any, on the equity shares of the Company. |
| Results | Inter-alia , to consider and approve the Unaudited Financial Results for the quarter ended June 30, 2015. |
| Results | To consider and approve the unaudited financial results for the quarter ended September 30, 2015. |
| Results | inter-alia, to consider and approve Unaudited Financial Results of the Company for the quarter ended December 31, 2015. |
| Results/Dividend | inter-alia, to consider amongst other things, approval of audited financial results (Standalone & Consolidated) for the quarter / year ended March 31, 2016 and to recommend dividend, if any, on the equity shares of the Company. |
| Results | inter-alia, to consider and approve Un-Audited Financial Results for the first quarter ended June 30, 2016. |
| Results | Inter-alia, to consider and approve Un-Audited Financial Results for the quarter and half year ended September 30, 2016. |
| Results | Inter-alia, to consider and approve Un-Audited Financial Results for the quarter and nine months ended December 31, 2016. |
| Results/Dividend | inter-alia, to consider amongst other things, approval of audited financial results (Standalone & Consolidated) for the quarter / year ended March 31,2017 and to recommend dividend, if any, on the equity shares of the Company. |
| Results | inter-alia, to consider and approve Un-Audited Financial Results for the first quarter ended June 30, 2017. |
| Results | Approval and declaration of Un-Audited Financial Results for the quarter ended June 30, 2017. |
| Results | inter-alia, to consider and approve Un-Audited Financial Results for the second quarter and half year ended September 30, 2017. |
| Results | inter-alia, to consider and approve Un-Audited Financial Results for the third quarter and nine months ended December 31, 2017. |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2018,to recommend dividend, if any on the equity shares of the Company and other business matters |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve Un-Audited Financial Results for the Quarter and Half Year ended 30th September 2018 |
| Financial Results | Pursuant to clause 33 of the Listing Obligations and Disclosure requirements (LODR), Regulations, 2015, this is to inform you that a meeting of the Board of Directors of our Company will be held on Monday, 4th February, 2019, inter-alia, to consider and approve Un-Audited Financial Results for the quarter and nine months ended 31st December, 2018. |
| Financial Results | to consider approval and declaration of Un-Audited Financial Results for the quarter and nine months ended December 31, 2018. |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2019, dividend and other business matters |
| Financial Results | Pursuant to clause 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), this is to inform you that a meeting of the Board of Directors of our Company will be held on Monday, 22nd July 2019, inter-alia, to consider approval of Un-audited financial results for the first quarter ended 30th June 2019. |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2019 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2020 and dividend if any |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2020 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2021 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 25-Jul-2022 to consider financial statements for the period ended June 2022 |
| Financial results | GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 11-Nov-2022 to consider financial statements for the period ended September 2022 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2024 and dividend |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
| Financial Results | GLAXO : 14-Feb-2025 : The Company has informed the Exchange that a Board meeting to be held on February 10, 2025 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on February 14, 2025, To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of GlaxoSmithKline Pharmaceuticals Limited
Voting Results of GlaxoSmithKline Pharmaceuticals Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 28-JUN-2024 | AGM | ORDINARY - To receive, consider and adopt the Audited Financial Statements (including Consolidated Financial Statements) of the Company for the financial year ended 31 March 2024 together with the Reports of the Board of Directors and Auditors thereon. |
| 28-JUN-2024 | AGM | Ratification of Remuneration to Cost Auditor. |
| 28-JUN-2024 | AGM | Appointment of Ms. Renu Sud Karnad as Non- Executive Director (DIN:00008064) |
| 28-JUN-2024 | AGM | To appoint a Director in place of Mr. Subesh Williams (DIN: 07786724), who retires by rotation and being eligible, offers himself for re-appointment. |
| 28-JUN-2024 | AGM | To declare Rs 32 per share Dividend on Equity Shares for the financial year ended 31 March 2024. |
| 26-JUL-2023 | AGM | To receive, consider and adopt the Audited Financial Statements. |
| 26-JUL-2023 | AGM | Ratification of Remuneration to Cost Auditor. |
| 26-JUL-2023 | AGM | To appoint a Director in place of Mr. Juby Chandy (DIN:09530618), who retires by rotation and being eligible, offers himself for re-appointment. |
| 26-JUL-2023 | AGM | To declare Dividend on Equity Shares for the financial year ended 31 March 2023. |
| 29-NOV-2022 | Postal Ballot | Appointment of Mr. Bhushan Akshikar (DIN: 09112346) as a Director |
| 29-NOV-2022 | Postal Ballot | Appointment of Mr. Bhushan Akshikar (DIN: 09112346) as a Managing Director |
| 26-JUL-2022 | AGM | To receive, consider and adopt the Audited Financial Statements (including Consolidated Financial Statements) of the Company for the financial year |
| 26-JUL-2022 | AGM | Ratification of Remuneration to Cost Auditor |
| 26-JUL-2022 | AGM | Appointment of Mr. Manu Anand as an Independent Director |
| 26-JUL-2022 | AGM | Re-Appointment of statutory Auditors |
| 26-JUL-2022 | AGM | To appoint a Director in place of Mr. Subesh Williams (DIN 07786724), who retires by rotation and being eligible, offers himself for re-appointment |
| 26-JUL-2022 | AGM | To declare Dividend on Equity Shares for the financial year ended 31 March 2022 |
| 21-APR-2022 | Postal Ballot | Re-Appointment of Mr. Sridhar Venkatesh (DIN: 07263117) as a Managing Director |
| 21-APR-2022 | Postal Ballot | Appointment of Mr. Juby Chandy (DIN:09530618) as a Whole-time Director & ChiefnFinancial Officer (CFO) |
| 21-APR-2022 | Postal Ballot | Appointment of Mr. Juby Chandy (DIN: 09530618) as a Director |
FAQs on GlaxoSmithKline Pharmaceuticals Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.